What is the current status of EOPYY biomarker coverage?
The approval of 11 new biomarkers for 39 cancer indications represents a significant regulatory step, but practical application is currently non-existent for many patients. Although the Ministry of Health has issued the necessary decision to correct previous errors from October 2025, the institutional framework remains unapplied in daily clinical practice. This means that while the tests are legally recognized, the mechanism for reimbursement and actual patient access is still being finalized.
The transition from legal approval to clinical availability is hindered by several administrative bottlenecks. Oncologists and patient advocates warn that these gaps create a high risk of delays, which can directly worsen patient outcomes by postponing the start of targeted therapies. The current situation is characterized by a disconnect between legislative progress and the actual ability of a patient to undergo testing and receive treatment.
The regulatory shift in diagnostic approvals
A major change in how these tests are managed was introduced in a law passed by Parliament in mid-summer 2026. Previously, the Ministry of Health held direct authority over the approval of new diagnostic tests. Under the new legislation, the responsibility for evaluating new tests as science advances has shifted to the Evaluation Committee (EAAFACH). This committee will also be responsible for the approval or rejection of the corresponding new therapies, creating a more centralized and specialized oversight mechanism for oncology care.
Why are delays in implementation affecting oncology patients?
Delays in the implementation of the new biomarker decision threaten the window of opportunity for effective cancer treatment. According to Manolis Salostros, President of the Hellenic Society of Oncologists and Pathologists (EOPE), biomarkers are not a luxury but an indispensable component of modern oncological care. He emphasizes that without immediate activation of the reimbursement process, the legal framework remains a theoretical exercise rather than a clinical reality.
The primary concerns regarding these delays include:
- Reimbursement activation: The financial mechanism that allows EOPYY to pay for these tests is not yet operational.
- Laboratory negotiations: EOPYY must complete negotiations with diagnostic laboratories to establish the economic coverage for patients.
- Appointment delays: There is a significant risk that patients will face long waiting periods for testing, which delays the commencement of life-saving treatments.
For patients, the inability to access these tests means that doctors cannot accurately identify the genetic characteristics of a tumor. This prevents the selection of the most appropriate, targeted therapy, potentially allowing the disease to progress during the administrative waiting period.
How is the Greek government addressing funding and quality?
The Ministry of Health has committed to increasing the budget to meet the actual needs of the patient population. Daphne-Eleni Nikolaou, General Secretary of Strategic Planning at the Ministry of Health, stated that the ministry has implemented targeted interventions to expand access to specialized biomarker testing. The government's financial strategy involves a phased increase in funding to ensure sustainability.
| Fiscal Year | Allocated Funding (Estimated) | Status/Goal |
|---|---|---|
| 2026 | €5 million | Current allocation for initial implementation |
| 2027 | €10 million | Projected budget based on Ministry studies |
Beyond mere funding, the government is focusing on the technical standards of the tests. According to Ms. Nikolaou, the EOPYY Negotiation Committee is expected to finalize its work by November 2026. This process will not only include the financial reimbursement rates but also the establishment of strict quality specifications that laboratories must meet to perform these highly sensitive molecular tests.
The challenge of the 'clawback' mechanism
A significant financial concern for diagnostic centers is the 'clawback' mechanism. This system requires diagnostic centers to provide mandatory discounts to EOPYY if the total expenditure for certain tests exceeds the pre-determined budget. There is apprehension that if the demand for new biomarker testing is higher than anticipated, the financial burden on laboratories could become unsustainable, potentially affecting the availability of the tests themselves.
What are the perspectives of patient advocates and oncologists?
Patient advocacy groups and medical professionals are calling for urgent action to bridge the gap between policy and practice. Giorgos Kapetanakis, President of the Hellenic Cancer Federation (ELLOK), highlighted that the initial budget estimate of €5 million was insufficient. Following a study conducted in early summer, it was determined that a minimum annual funding of €10 million is required to cover the actual needs of Greek patients.
Medical professionals are also stressing the importance of testing accuracy. Kapetanakis noted that any discrepancies in test results across different laboratories could lead to incorrect treatment decisions. Therefore, the accreditation of laboratories is just as critical as the availability of funds. If the molecular analysis is inconsistent, the entire foundation of personalized oncology is compromised.
Frequently asked questions
What are biomarkers in the context of cancer?
Biomarkers are biological indicators, often found through genetic testing, that reveal specific characteristics of a tumor. They allow oncologists to identify which specific drugs will be most effective against a particular type of cancer, enabling a personalized approach to treatment rather than a one-size-fits-all method.
When will EOPYY start paying for these tests?
The Ministry of Health expects the EOPYY Negotiation Committee to complete its processes by November 2026. Once these negotiations with laboratories are finalized and the reimbursement decision is signed, the financial coverage for patients should officially begin, though the exact date remains dependent on these administrative steps.
Why was the previous decision from 2025 corrected?
The decision issued in October 2025 contained errors that necessitated a full year of corrections. The updated decision, which was recently published, aims to clarify the specific medical indications and the precise methodologies required to perform the tests, ensuring a more reliable framework for both doctors and patients.
Is the funding sufficient for all patients?
Current estimates suggest that the initial €5 million allocated for 2026 may be insufficient. Patient advocates and Ministry studies suggest that an annual budget of at least €10 million is necessary to ensure that all patients who require these specialized molecular tests can access them without financial barriers.
Can any laboratory perform these biomarker tests?
No, not all laboratories will be permitted to perform these tests. The EOPYY Negotiation Committee is currently working to establish specific quality standards and technical specifications. Only laboratories that meet these rigorous medical and technical criteria will be authorized to conduct the tests under the new reimbursement scheme.
Key takeaways
- EOPYY has approved 11 new biomarkers for 39 cancer indications to improve personalized treatment.
- The Ministry of Health plans to increase annual funding from €5 million in 2026 to €10 million in 2027.
- The responsibility for approving new diagnostic tests has moved from the Ministry to the EAAFACH committee.
- Implementation is currently delayed pending laboratory negotiations and the activation of reimbursement mechanisms.
The path toward equitable oncology care
The approval of new biomarker coverage is a vital victory for precision medicine in Greece, yet it remains a hollow victory until the administrative machinery catches up with scientific progress. The transition from legislative approval to bedside application is fraught with financial and logistical hurdles, from the 'clawback' risks for laboratories to the urgent need for increased state funding. Ensuring that these tests are not just legally available, but practically accessible and medically standardized, is the next critical challenge for the Greek healthcare system. Only then can the promise of targeted cancer therapy be fulfilled for all patients.
